Edition:
United Kingdom

Michael Erman

UPS eyes in-home health services with U.S. vaccine project

22 Mar 2019

LOUISVILLE, Ky. - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare. | Video

UPS eyes in-home health services with U.S. vaccine project

22 Mar 2019

LOUISVILLE, Ky. - United Parcel Service Inc wants to get beyond U.S. doorsteps with a new push into healthcare.

Starboard joins opposition to Bristol-Myers' $74 billion Celgene deal

28 Feb 2019

Activist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co's second-largest investor, Wellington Management, in opposing the drugmaker's $74 billion purchase of biotech Celgene Corp on Thursday, sowing further doubt on what would be the largest pharmaceutical takeover ever.

Top Bristol-Myers shareholder comes out against $74 billion Celgene deal

28 Feb 2019

Bristol-Myers Squibb Co's top shareholder Wellington Management said on Wednesday it does not support the U.S. drugmaker's $74 billion deal to buy biotech Celgene Corp, imperiling what would be the largest pharmaceutical acquisition of all time.

U.S. senators tell drug company executives pricing is 'morally repugnant'

26 Feb 2019

WASHINGTON/NEW YORK U.S. senators called drug pricing practices "morally repugnant" and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate hearing on the rising costs of prescription medicines.

Drug company executives to testify before U.S. Senate

26 Feb 2019

WASHINGTON/NEW YORK Seven drug company executives will testify about rising prescription drug prices before a powerful U.S. Senate Committee on Tuesday, marking a sharp escalation in lawmakers' promises to address high medicine costs.

Teva Pharm sees weaker than expected 2019, shares tumble

13 Feb 2019

TEL AVIV/NEW YORK Teva Pharmaceutical Industries forecast lower revenue and profit for 2019 on Wednesday, missing analysts' expectations, as it faces generic competition for two key branded drugs. | Video

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

11 Feb 2019

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

World News